14 January 2019 - The government shutdown could soon jeopardise highly anticipated new drugs from Janssen, Sanofi, and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies.

President Trump has warned that the shutdown — already the longest in history — could stretch on for “months or even years.” And though the FDA can retain more than half of its workforce thanks to application fees paid by drug and device makers, Commissioner Scott Gottlieb has cautioned the agency only has about three more weeks’ worth of funding to draw down.

Read Stat News article